WHO ICTRP trial
Is the gut microbiome associated with residual beta cell function in…
NL-OMON49369 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON49369 |
|---|---|
| Public title | Is the gut microbiome associated with residual beta cell function in longstanding type 1 diabetes? |
| Scientific title | Is the gut microbiome associated with residual beta cell function in longstanding type 1 diabetes? - GUTDM1: Residual beta cell function and microbiome in type 1 diabetes |
| Primary sponsor | Academisch Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | Juvenile diabetes type 1 diabetes;10018424;Juvenile diabetes;type 1 diabetes |
| Interventions | ;Beta cell function;Microbiome;Type 1 diabetes |
| Registration date | Sep 8, 2020 |
| Target size | 500 |
| Secondary IDs | NL73189.018.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: